Dare Bioscience Inc (NASDAQ:DARE) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 566,690 shares, a decrease of 33.6% from the April 30th total of 853,637 shares. Based on an average daily volume of 1,204,770 shares, the short-interest ratio is presently 0.5 days. Currently, 5.6% of the company’s stock are short sold.
Shares of Dare Bioscience traded up $0.07, hitting $1.38, during midday trading on Thursday, according to Marketbeat Ratings. The company had a trading volume of 294,100 shares, compared to its average volume of 898,336. Dare Bioscience has a twelve month low of $0.74 and a twelve month high of $12.40. The stock has a market capitalization of $16.91 million, a price-to-earnings ratio of -1.11 and a beta of 2.74.
Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Monday, April 2nd. The biotechnology company reported ($0.49) EPS for the quarter. research analysts forecast that Dare Bioscience will post -1.26 earnings per share for the current fiscal year.
In related news, Director Roger Hawley bought 140,000 shares of the company’s stock in a transaction that occurred on Monday, June 11th. The shares were purchased at an average cost of $1.45 per share, with a total value of $203,000.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 19.00% of the company’s stock.
A hedge fund recently bought a new stake in Dare Bioscience stock. CVI Holdings LLC bought a new stake in shares of Dare Bioscience Inc (NASDAQ:DARE) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 471,661 shares of the biotechnology company’s stock, valued at approximately $395,000. Dare Bioscience makes up about 0.5% of CVI Holdings LLC’s portfolio, making the stock its 22nd biggest position. CVI Holdings LLC owned approximately 4.13% of Dare Bioscience as of its most recent filing with the SEC. 9.04% of the stock is owned by institutional investors.
About Dare Bioscience
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.